FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ARMEN GARO H
2. Issuer Name and Ticker or Trading Symbol

AGENUS INC [ AGEN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chairman and CEO
(Last)          (First)          (Middle)

C/O AGENUS INC, 3 FORBES ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

11/5/2019
(Street)

LEXINGTON, MA 02421
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy)  $3.23  11/5/2019    A     87500       (1) 11/5/2029  Common Stock  87500  $0  87500  D   

Explanation of Responses:
(1)  Option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan. Option vests over a three-year period, with 1/3 of Option vesting November 5, 2020, and the balance vesting in equal quarterly installments thereafter.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ARMEN GARO H
C/O AGENUS INC
3 FORBES ROAD
LEXINGTON, MA 02421
X
Chairman and CEO

Signatures
/s/Evan D. Kearns, as Attorney-in-Fact for Garo H. Armen 11/7/2019
**Signature of Reporting Person Date


Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Agenus Charts.
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Agenus Charts.

Agenus Inc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Agenus Reports First Quarter 2024 Results
Tuesday 7 May 2024 (3 hours ago) • Business Wire
Form 8-K - Current report
Tuesday 7 May 2024 (3 hours ago) • Edgar (US Regulatory)
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 7 May 2024 (3 hours ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 7 May 2024 (3 hours ago) • Edgar (US Regulatory)
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
Wednesday 1 May 2024 (6 days ago) • Business Wire
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
Wednesday 24 April 2024 (2 weeks ago) • Business Wire
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Tuesday 23 April 2024 (2 weeks ago) • Business Wire
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
Friday 12 April 2024 (4 weeks ago) • Business Wire
Agenus Announces Reverse Stock Split of Common Stock
Friday 5 April 2024 (1 month ago) • Business Wire
Agenus Reports Fourth Quarter and Full Year 2023 Results
Thursday 14 March 2024 (2 months ago) • Business Wire
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
Wednesday 6 March 2024 (2 months ago) • Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 5 March 2024 (2 months ago) • Business Wire